Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage

阿糖胞苷 氟达拉滨 柔红霉素 背景(考古学) 细胞周期 生物 髓系白血病 癌症研究 白血病 细胞凋亡 化疗 免疫学 遗传学 古生物学 环磷酰胺
作者
Kartika Venugopal,Jianping Li,Daniil E. Shabashvili,Luisa M. Posada,Yang Feng,Daphné Dupéré-Richer,Aditya Bele,Jonathan D. Licht,Olga A. Guryanova
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 2643-2643 被引量:2
标识
DOI:10.1182/blood-2018-99-118708
摘要

Abstract Mutations in the DNA methyltransferase 3A (DNMT3A) gene are recurrent in de novo acute myeloid leukemia (AML) (20-35%) and are associated with poor prognosis. Although studies demonstrated survival benefit after daunorubicin dose intensification for DNMT3A mutant AML, these patients tend to be older (median age at diagnosis 67 y.o. in DNMT3A-mutated cases compared to 60 y.o. in DNMT3A-WT) and more likely to be unfit for high-dose chemotherapy. In older patients, cytarabine monotherapy, a nucleoside analog chain terminator that stalls DNA replication, may be preferred due to lower toxicity. However, its efficacy in DNMT3A mutant AML has not been evaluated. Previous gene expression studies in large AML cohorts and in a mouse model of Dnmt3a-mutant hematopoiesis demonstrated negative enrichment of the cell cycle related signatures, including G2/M checkpoint and E2F targets. Hence, we hypothesized cell cycle-specific drugs cytarabine and fludarabine may be effective in DNMT3A-mutant context. DNMT3A mutant AML cell lines (MUT) SET-2 and KO-52 were more sensitive to cytarabine and fludarabine than DNMT3A wild-type (WT) cells KU-812 and K-562 in vitro (cytarabine IC50 46.1 and 165.8 μM in MUT SET-2 and KO-52 compared to 465.2 μM and not reached in WT KU-812 and K-562, respectively; fludarabine IC50 1.1 and 1.3 μg/ml in MUT vs 16 μg/ml and not reached in WT, Figure 1A). Higher proportion of cells with mutant DNMT3A were undergoing apoptosis 24 hours after cytarabine exposure (26.5±2.3% and 13.1±2.3% Annexin V+ cells in SET-2 and KO-52 vs 6.9±2.6% and 4.6±2.5% in KU-812 and K-562, respectively, p<0.05). Analysis of the DNA damage signaling revealed increased levels of phospho-CHK1, γH2A.X, and cleaved PARP (stalled replication forks, DNA damage, and apoptosis markers). To investigate the mechanism of differential sensitivity to cytarabine-induced DNA damage, we overexpressed WT or R882 mutant forms of DNMT3A in U2OS cells, a well-established model for DNA damage studies. MUT cells were more sensitive to cytarabine compared to WT (IC50 38 μM vs 213 μM after 48 hours of exposure, Figure 1B), which was accompanied by increased apoptosis (22.3±7.6% in MUT vs 7.2±0.3% in WT Annexin V+ cells, p<0.03). DNMT3A-MUT cells showed persistence of the phospho-CHK1 levels over 12 hours of continuous cytarabine exposure, whereas WT showed resolution of the CHEK1 signaling after initial activation. Consistently, MUT cells accumulated significantly more DNA damage over 36 hours of continuous exposure compared to WT, as evidenced by γH2A.X immunofluorescent staining, and by Comet assay (Figure 1C). Fewer MUT cells were able to complete replication and progress to the G2 phase of the cell cycle (5.3±0.2% in MUT vs 11.2±0.6% in WT, flow-cytometric analysis by DNA content, p<0.01). Notably, both WT and MUT cells were proficient in DNA repair by homologous recombination (HR, tested by RAD51 foci formation visualized by immunofluorescence) and by non-homologous end joining (NHEJ, 53BP1 foci). These data demonstrate that enhanced sensitivity to cytarabine in cells expressing mutant DNMT3A is due to increased susceptibility to DNA damage during replication, and not to defects in DNA repair. Consistently, even though MUT cells showed more DNA damage by Comet assay after 12 hours of cytarabine treatment, it was largely repaired 60 minutes after drug wash-out, similar to WT, Figure 1D). These observations support continuous infusion of cytarabine as a delivery method of choice in the clinic, rather than bolus administration. Finally, bone marrow cells derived from Dnmt3a-mut conditional knock-in mice showed impaired clonogenic survival in MethoCult when exposed to 25 nM cytarabine ex vivo, compared to Dnmt3a-WT (p<0.003). We are currently investigating gene expression, DNA methylation, and chromatin accessibility profiles in WT and MUT cells; and cytarabine efficacy in a pre-clinical mouse model of Dnmt3a(mut):Flt3(ITD):Npm1(c) leukemia. In conclusion, our studies show cells with DNMT3A mutations may be sensitive to DNA damage induced by clinically relevant nucleoside analogs such as cytarabine. Our data support continuous infusion of cytarabine rather than bolus administration, and establish its mechanistic basis. These results demonstrate, in addition to its role in epigenetic control, DNMT3A contributes to preserving genome integrity during DNA replication. Figure 1. Figure 1. Disclosures Licht: Celgene: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Ming完成签到,获得积分10
1秒前
2秒前
11完成签到,获得积分10
2秒前
江添盛望完成签到,获得积分10
2秒前
2秒前
贻嘉完成签到,获得积分10
3秒前
NexusExplorer的应助被Brave采纳,获得10
3秒前
Jin发布了新的文献求助30
3秒前
why完成签到 ,获得积分10
3秒前
忘了去记得完成签到 ,获得积分10
3秒前
小汤圆完成签到,获得积分10
3秒前
zyf发布了新的文献求助10
4秒前
刘彤发布了新的文献求助10
5秒前
娜娜完成签到,获得积分20
5秒前
etheral发布了新的文献求助10
7秒前
111发布了新的文献求助10
7秒前
7秒前
王乐乐发布了新的文献求助10
8秒前
hmj完成签到,获得积分10
8秒前
小马甲的应助被安静季节采纳,获得10
8秒前
Jigsaw发布了新的文献求助10
8秒前
大个的应助被mmmml采纳,获得10
9秒前
10秒前
暮念给暮念的求助进行了留言
10秒前
10秒前
15311533181完成签到,获得积分10
11秒前
vnewgnl的应助被torfun采纳,获得10
11秒前
cookie完成签到,获得积分10
11秒前
Jasper的应助被1123采纳,获得10
11秒前
hahdong完成签到,获得积分10
11秒前
12秒前
ket的应助被火山采纳,获得10
12秒前
12秒前
12秒前
blossem发布了新的文献求助10
14秒前
111发布了新的文献求助20
14秒前
hetaoren完成签到,获得积分10
15秒前
ke完成签到,获得积分20
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192078
求助须知:如何正确求助?哪些是违规求助? 9578698
关于积分的说明 21861559
捐赠科研通 7791583
什么是DOI,文献DOI怎么找? 3436814
关于科研通互助平台的介绍 2560538
邀请新用户注册赠送积分活动 2483582